Skip to main content
Premium Trial:

Request an Annual Quote

Generics on Their Mind

Sanofi-Aventis will be expanding into generics, says the Wall Street Journal, while cutting its research and development. The generic group will be reshuffled to focus on emerging markets where drug sales are on the rise. The Health Blog adds that Sanofi recently bought two Latin American generic-drug companies as well as a Czech one. The Health Blog also notes that Johnson & Johnson is contemplating selling generics outside the US, Pfizer has a deal with Aurobindo Pharma and Claris Lifesciences to market generics in emerging markets, and that AstraZeneca, Merck, and Novartis are also dipping their toes into generics.

On a related note, Japan has approved its first generic biotech drug, Somatropin. This Novartis drug treats growth hormone deficiency in children or associated with Turner's syndrome or chronic renal insufficiency.

The Scan

Vaccine Update Recommended

A US Food and Drug Administration panel recommends booster vaccines be updated to target Omicron, CNBC reports.

US to Make More Vaccines for Monkeypox Available

The US is to make nearly 300,000 vaccine doses available in the coming weeks to stem the spread of human monkeypox virus, according to NPR.

Sentence Appealed

The Associated Press reports that Swedish prosecutors are appealing the sentence given to a surgeon once lauded for transplanting synthetic tracheas but then convicted of causing bodily harm.

Genome Biology Papers on COVID-19 Effector Genes, Virtual ChIP-seq, scDART

In Genome Biology this week: proposed COVID-19 effector genes, method to predict transcription factor binding patterns, and more.